Evidence map›Paper›PMID 42373609›Full record

ArticleCell discovery2026

Longitudinal single-cell and TCR repertoire profiling characterizes clonal entrapment in patients with pMMR/MSS locally advanced rectal cancer.

Zhichun Tang, Mingxuan Zhu, Shidong Zhao, Dazhi Pang, Yancheng Cui, Guole Lin, Aiwen Wu, Yilin Lin, Xinyang Jiang, Wei Zhang and 7 more

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in Cell discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06493240 (Neoadjuvant Long-course Chemoradiotherapy Followed by PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06493240 phase2completednot on this map

Neoadjuvant Long-course Chemoradiotherapy Followed by PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer

TypeinterventionalSponsorPeking University People's HospitalRan2023 to 2025Enrolled30ConditionsLocally Advanced Rectal CancerArmsradiation, PD-1 Monoclonal Antibody, TME surgery
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Zhichun Tang *Biomedical Pioneering Innovation Center (BIOPIC) and School of Life Sciences, Peking-Tsinghua Center for Life Sciences (CLS), State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Peking University, Beijing, China.
Mingxuan Zhu *Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
Shidong Zhao *Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
Dazhi Pang *School of Basic Medical Sciences, Tsinghua University, Beijing, China.
Yancheng CuiDepartment of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
Guole LinDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Aiwen WuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China.ORCID http://orcid.org/0000-0003-3365-3481
Yilin LinDepartment of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
Xinyang JiangVanke School of Public Health, Tsinghua University, Beijing, China.
Wei ZhangDepartment of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
Nan XiongDepartment of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
Changjiang YangDepartment of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
Caihong WangDepartment of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
Shan WangDepartment of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.ORCID http://orcid.org/0000-0003-3396-5936
Yingjiang YeDepartment of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
Fan BaiBiomedical Pioneering Innovation Center (BIOPIC) and School of Life Sciences, Peking-Tsinghua Center for Life Sciences (CLS), State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Peking University, Beijing, China. fbai@pku.edu.cn.ORCID http://orcid.org/0000-0001-6119-8936
Zhanlong ShenDepartment of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China. shenzhanlong@pku.edu.cn.ORCID http://orcid.org/0000-0002-8717-2686

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82241230National Natural Science Foundation of China (National Science Foundation of China) 82272841National Natural Science Foundation of China (National Science Foundation of China) 82341007National Natural Science Foundation of China (National Science Foundation of China) U24A20737Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) L234036Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) Z220014
6 · The paper itself

Abstract

Elevated intratumoral immune inflammation prior to treatment is typically associated with better outcomes in hot tumors treated with immune checkpoint inhibitors (ICIs). However, we observed a paradox in pMMR/MSS locally advanced rectal cancer (LARC) patients, where a subset with elevated baseline immune inflammation exhibited worse outcomes after combined radiotherapy and ICI treatment compared with patients with minimal immune inflammation. To investigate this counterintuitive finding, we performed paired scRNA-seq and scTCR-seq on longitudinally collected samples, including tumor biopsies (pre-treatment, post-radiotherapy, and post-immunotherapy) and peripheral blood mononuclear cells (pre-treatment and post-immunotherapy), from 20 pMMR/MSS LARC patients treated with sequential radiotherapy and ICI therapy (NCT06493240). We propose the concept of clonal entrapment to explain this phenomenon. Specifically, our profiling results reveal that increased HLA-DQA2 expression in dendritic cells and upregulated GDF15 expression in treatment-resistant tumor cells correlate with the restricted expansion of novel tumor-reactive TCR clonotypes. Consequently, the immune response is limited primarily by pre-existing TCR clonotypes within the tumor, especially those partially expanded under chronic inflammation, leading to the expansion of TCR clonotypes derived mainly from pre-treatment CD8

Identifiers

PMID42373609
PMCPMC13315945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.